Coherus BioSciences Dividend

Dividend criteria checks 0/6

Coherus BioSciences no tiene antecedentes de pago de dividendos.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.8%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$2.11
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Mar 21

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Feb 03

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Jan 17

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Dec 20

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

May 13

Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3

Sep 19

Coherus: 2022 Is In Many Ways A Make Or Break Year

Aug 24

Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli

Aug 03

Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer

Jul 06

Stability and Growth of Payments

Fetching dividends data

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de CHRS han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de CHRS han aumentado.

Dividend Yield vs Market

Coherus BioSciences Dividend Yield vs Market

How does CHRS dividend yield compare to the market?
Segment	Dividend Yield
Company (CHRS)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Biotechs)	2.8%
Analyst forecast in 3 Years (CHRS)	0%

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de CHRS en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de CHRS en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Earnings Payout to Shareholders

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de reparto de CHRS para determinar si sus dividendos están cubiertos por los beneficios.

Cash Payout to Shareholders

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que CHRS no ha comunicado ningún pago.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Coherus BioSciences Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Consensus EPS estimates upgraded to US$0.55 loss, revenue downgraded

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Forecast breakeven date pushed back to 2026

Coherus BioSciences, Inc. to Report Q4, 2023 Results on Mar 13, 2024

New major risk - Financial position

Coherus BioSciences, Inc. Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Lead Independent Director exercised options to buy US$139k worth of stock.

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million.

Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million.

Coherus BioSciences, Inc. Presents Positive Phase 2 Clinical Data on Casdozokitug, A First-In-Class IL-27-Targeted Antibody, At the 2024 ASCO GI Cancers Symposium

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Coherus BioSciences, Inc. Appoints Bryan McMichael as Principal Financial Officer

Coherus BioSciences, Inc. Announces Resignation of McDavid Stilwell as Chief Financial Officer, Effective December 31, 2023

Coherus BioSciences, Inc. Presents Phase 1/2 Clinical Data on Casdozokitug at the 2023 ESMO Immuno-Oncology Congress

Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

Chairman notifies of intention to sell stock

Consensus revenue estimates fall by 12%

New major risk - Share price stability

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target increased by 7.3% to US$12.88

Coherus BioSciences, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Coherus BioSciences, Inc. Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Price target decreased by 7.6% to US$12.11

Coherus Biosciences, Inc. Announces Resubmission of Biologics License Application (Bla) Supplement for Udenyca(R) Onbody

FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus BioSciences, Inc Also Announces Completion of Toripalimab FDA Inspections

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Coherus Biosciences, Inc. Provides Revenue Guidance for the Year 2023

Coherus BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Coherus Biosciences, Inc. Announces Appointment of Michael Ryan to Board of Directors

Coherus Launches Yusimry™, A Biosimilar of Humira®

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Price target decreased by 12% to US$13.63

Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Price target decreased by 13% to US$15.56

Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Consensus revenue estimates fall by 13%

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

Coherus BioSciences, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$1.09 loss

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Coherus BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology

Coherus to Launch Cimerli (Ranibizumab-Eqrn) in the United States on October 3, 2022

Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3

Coherus BioSciences, Inc. Announces Executive Changes

Coherus: 2022 Is In Many Ways A Make Or Break Year

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity

Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli

Coherus BioSciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer

Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?

Price target decreased to US$18.75

Coherus: Will Its Chinese Gambit Fail?

Price target decreased to US$21.14

Coherus BioSciences Appoints Jill O’Donnell-Tormey to Its Board of Directors, Nominating and Corporate Governance Committee of the Board of Directors

Consensus revenue estimates fall by 17%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Coherus Biosciences, Inc. Appoints Charlie Newton to Board of Directors, Member of Audit Committee

Coherus BioSciences, Inc. to Report Q1, 2022 Results on May 05, 2022

High number of new and inexperienced directors